Another hepatitis B drug is available, serum virus levels can be reduced by 99.99%
April 20, 2016 Source: Bio Valley
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];Recently, the hepatitis B drug field has revived, and American biotechnology company Arrowhead has released its clinical data of phase IIb of the hepatitis B drug candidate ARC-520, which is used in combination with Bristol-Myers Squibb (BMS) hepatitis B drug Baraclude (entecavir) for the treatment of refractory HBeAg-negative chronic hepatitis B patients. The results showed that in the ARC-520+Baraclude treatment group, serum HBV DNA levels were significantly reduced by 99.99%, which surprised the industry with miraculous effects.
On the day of the news release, Arrowhead's share price soared 16.35%, the highest level was 6.12 US dollars, and finally closed at 5.94 US dollars, the day's increase of 12.93%. At the same time, Arrowhead attracted a large number of pharmaceutical companies to follow up on the acquisition, including Gilead.
ARC-520, a drug designed based on RNA interference (RNAi) technology, interferes with the reverse transcription process of hepatitis B virus by acting on messenger RNA (mRNA) targets for the treatment of chronic hepatitis B. ACR-520 uses Arrowhead's unique Dynamic Polyconjugates delivery system. The principle is to block the expression of certain proteins of hepatitis B virus through RNA interference, resulting in the virus not proliferating, and then using the human immune system to remove the remaining virus. Immune clearant state, characterized by seroconversion of hepatitis B surface antigen (HBsAg) with or without serological conversion.
At present, there are about 400 million people in the world suffering from hepatitis B, of which 16 million are distributed in the United States and Europe. The global average annual incidence of new hepatitis B cases is about 10-30 million, with an average of 1-2 deaths per minute. After hepatitis B virus infection, as the disease progresses, it can gradually develop into cirrhosis and liver cancer. According to some data, 80% of primary liver cancer is associated with hepatitis B virus infection.
As we all know, the preventive hepatitis B vaccine has been put into use since 1982, and it has contributed to the prevention of hepatitis B transmission. After hepatitis B virus infection, the current treatment drugs still can not achieve complete cure. If ARC-520 can truly achieve the claimed "functional cure", it is undoubtedly expected to become a new blockbuster in the field of hepatitis B, the authority in the field of hepatitis B - Gilead, Bristol-Myers Squibb, Johnson & Johnson, and ContraVir Pharmaceuticals are stressful.
For this good news, Arrowhead CEO Anzalone said with a smile that after the phase IIb clinical trial confirmed the outstanding efficacy of ARC-520 in the treatment of hepatitis B, we will continue to conduct experimental research on multi-dose and multi-combination therapy for ARC-520. With the help of ARC-520, it is possible to achieve the removal and defense of hepatitis B virus by the autoimmune system, thereby obtaining functional radical cure of hepatitis B.
Some analysts predict that ARC-520 is expected to be listed in 2020 and is expected to reach a total annual sales of 4.5 billion US dollars. And for Gilead, it really poses no small challenge. At present, Gilead has listed hepatitis B treatment drugs mainly including: Hespera and Viread, and three other drug candidates are still in the clinical stage. Viread is a nucleotide-based reverse transcriptase inhibitor that was approved by the FDA in 2008 and has gradually become a Gilead generation of gold-absorbing devices in recent years. According to statistics, Viread's 2015 annual sales exceeded 1.11 billion US dollars, an increase of 4.73% compared with the same period last year. The analysis said that 2016 is expected to continue to maintain sales prospects of 1.12 billion US dollars.
In addition to the pressure from other pharmaceutical companies to introduce new varieties of hepatitis B treatment, Gilead's own hepatitis B product line research and development is also deadlocked. In May last year, the therapeutic vaccine GS-4774 developed by Gilead in cooperation with GlobeImmune did not reach the primary endpoint in the Phase II clinical trial (GS-US-330-0101) for the treatment of chronic hepatitis B virus (HBV) infection. Effectively reduce serum levels of hepatitis B surface antigen (HBsAg). Coupled with the affirmation of the efficacy of this ARC-520, it is undoubtedly worse for Gilead, and the revenue from its two hepatitis B drugs is somewhat dwarfed by the industry's expectations for ARC-520.
Faced with the crisis of no new products in the hepatitis B market and the slowdown in the growth of the hepatitis C market, Rugild can seize this opportunity to successfully acquire Arrowhead to broaden its hepatitis B treatment line, and to strengthen the position of hepatitis B overlord is just around the corner.
Freeze-dried powder is a sterile powder injection obtained by freezing the liquid medicine into a solid state in a sterile environment, and subliming and drying the water in a vacuum. Freeze-dried powder is composed of a bottle of high-purity and high-active biological protein freeze-dried powder and a high-purity liquid essence. When using, it needs to be connected with a patented vacuum to reconstitute the freeze-dried powder and the essence to activate the biological protein activity.
Freeze Dried Fruit Powder,Strawberry Powder,Freeze Dried Powder,Raspberry Powder
YT(Xi'an) Biochem Co., Ltd. , https://www.ytherblifes.com